Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06008795 · ClinicalTrials.gov registry record · Phase 2

BLOCK-SAH - PPF-Block for Post-SAH Headache

A Phase 2 study of Headache and Subarachnoid Hemorrhage, Aneurysmal, sponsored by University of Florida.

Recruiting
Registry status
Phase 2
Development phase
195
Enrollment target
11
Study locations

NCT06008795 is a Phase 2 study of Headache and Subarachnoid Hemorrhage, Aneurysmal that is actively recruiting participants, run by University of Florida. The registered enrollment target is 195 participants, above the 150-participant average among 35 other Headache trials with a reported enrollment target (30% higher). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06008795, a Phase 2 study of Headache and Subarachnoid Hemorrhage, Aneurysmal, is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
Phase 2
Development phase
195 participants
Enrollment target
11
Study locations

Study Summary

BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for headache in survivors of aneurysmal subarachnoid hemorrhage (SAH), while monitoring intracranial arterial mean flow velocities with transcranial Doppler (TCD) peri-intervention (intervention = PPF-injections: active or placebo)

Conditions Studied

Headache Subarachnoid Hemorrhage, Aneurysmal

Interventions

  • DRUG Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone
  • PROCEDURE Placebo Pteryogpalatine Fossa Injection

Study Locations (11)

New York

  • Albany Medical College - Albany
  • University of Rochester Medical College - Rochester

Florida

  • University of Florida - Gainesville

Georgia

  • Emory University - Atlanta

Maryland

  • University of Maryland Baltimore - Baltimore

Minnesota

  • Mayo Clinic - Rochester

Ohio

  • University of Cincinnati - Cincinnati

Oregon

  • Oregon Health and Sciences University - Portland

Pennsylvania

  • Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 195 participants
Start Date 2023-12-17
Est. Completion 2027-02-28
Phase Phase 2

Sponsor

University of Florida

1,106 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06008795

The ClinicalTrials.gov registry entry for NCT06008795 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 195 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 150-participant average among 35 other Headache trials with a reported enrollment target (30% higher). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Headache appearing as the primary indexed condition, and to 2 interventions - of which Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone is the first listed.

NCT06008795 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT06008795 about?

NCT06008795 is a clinical study titled "BLOCK-SAH - PPF-Block for Post-SAH Headache". BLOCK-SAH is a phase II, multicenter, randomized, double-blinded, placebo-controlled clinical trial with a sequential parallel comparison design (SPCD) of bilateral pterygopalatine fossa (PPF) injections with 20mg ropivacaine + 4mg dexamethasone (active, PPF-block) compared to saline (placebo) for h...

What is the current status of trial NCT06008795?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 195 participants. The study started on 2023-12-17. Estimated completion is 2027-02-28.

What conditions does trial NCT06008795 study?

This clinical trial studies the following conditions: Headache, Subarachnoid Hemorrhage, Aneurysmal.

What interventions are being tested in trial NCT06008795?

The interventions under investigation include: Pterygopalatine Fossa Nerve Block with Ropivacaine and Dexamethasone (DRUG), Placebo Pteryogpalatine Fossa Injection (PROCEDURE).

Who is sponsoring clinical trial NCT06008795?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06008795 being conducted?

This trial has 11 study locations across Florida, Georgia, Maryland, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Headache

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Headache

All registered trials for this condition

Subarachnoid Hemorrhage, Aneurysmal

All registered trials for this condition

Florida

All trials with a study site in Florida

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.